Observational Study Comparing Early and Late Ofatumumab Treatment in Adults with Relapsing Multiple Sclerosis in Portugal

What this Trial Is About

Researchers are studying the use of Ofatumumab in adults with Relapsing Multiple Sclerosis RMS in Portugal. The study compares patients who started Ofatumumab within three years of their RMS diagnosis to those who began treatment more than three years after diagnosis. This observational research aims to understand the effectiveness of Ofatumumab during routine medical care. Participants are divided into two groups based on the timing of their Ofatumumab treatment initiation. Data will be collected over a maximum of 24 months during three scheduled visits. If a patients disability score worsens at the 12- or 24-month visit, an additional visit will confirm this change. Patients must have started Ofatumumab within 12 months before joining the study or begin treatment at the time of inclusion. Throughout the study, patients will complete various assessments including questionnaires on MS impact, fatigue, and treatment satisfaction at baseline, 12 months, and 24 months. Researchers will measure the proportion of patients showing no evidence of disease activity NEDA-3 between months 12 and 24. The study includes monitoring treatment discontinuation and collects data under routine care conditions over two years.

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study